fda declaratory order semaglutide shortage resolved Issues on Resolution of Drug FDA declares semaglutide (Ozempic/Wegovy) shortage
Description
Office of Disease Prevention and Health Promotion
Some participants at moderate doses experienced more diarrhea than those at the highest dose
Over a 72-week period, individuals treated with tirzepatide lost an average of 20.2% of their weight, while those on semaglutide saw an average loss of 13.7%
Taking more or less than prescribed can lead to unintended and potentially harmful side effects
